Literature DB >> 18070282

Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions.

Y Ofran1, I Avivi, A Oliven, I Oren, T Zuckerman, L Bonstein, J M Rowe, E J Dann.   

Abstract

INTRODUCTION: The role of granulocyte transfusions (GT) in patients with neutropenia-related infections remains controversial.
MATERIALS AND METHODS: A retrospective analysis of 47 neutropenic patients, treated with 348 consecutive GTs for life-threatening infections between 1999 and 2004, is presented.
RESULTS: The only grade III-IV toxicity observed in GT recipients was respiratory deterioration (n = 6, 12.8%). The overall infection-related mortality (IRM) approached 38%. Achievement of a neutrophil count of > 700 cells per microl after at least 50% of days of GTs (n = 33, 70%) significantly correlated with reduced IRM (27.3% vs. 64.3%, P < 0.02). GT doses of > 2 x 10(10) neutrophils per bag appeared to increase both neutophil and platelet counts following transfusion.
CONCLUSION: GTs are safe and should be considered for patients with life-threatening neutropenic infections. However, prospective randomized studies of GTs are the only way to establish the true role of GTs.

Entities:  

Mesh:

Year:  2007        PMID: 18070282     DOI: 10.1111/j.1423-0410.2007.00971.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  14 in total

1.  Granulocyte transfusion therapy: randomization after all?

Authors:  Agata Drewniak; Taco W Kuijpers
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

2.  Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.

Authors:  Karen Quillen; Edward Wong; Phillip Scheinberg; Neal S Young; Thomas J Walsh; Colin O Wu; Susan F Leitman
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

3.  Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils.

Authors:  Barbara J Bryant; Yu Ying Yau; Phyllis J Byrne; David F Stroncek; Susan F Leitman
Journal:  Transfusion       Date:  2010-01-22       Impact factor: 3.157

Review 4.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 5.  Neutrophil biology and the next generation of myeloid growth factors.

Authors:  David C Dale
Journal:  J Natl Compr Canc Netw       Date:  2009-01       Impact factor: 11.908

6.  The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience.

Authors:  Karen Quillen; Yu Ying Yau; Susan F Leitman
Journal:  Transfusion       Date:  2008-11-19       Impact factor: 3.157

7.  Membrane permeability of the human granulocyte to water, dimethyl sulfoxide, glycerol, propylene glycol and ethylene glycol.

Authors:  Alex M Vian; Adam Z Higgins
Journal:  Cryobiology       Date:  2013-11-20       Impact factor: 2.487

8.  Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone.

Authors:  Karen Quillen; Phyllis Byrne; Yu Ying Yau; Susan F Leitman
Journal:  Transfusion       Date:  2009-03       Impact factor: 3.157

9.  Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion.

Authors:  Idil Yenicesu; Gülsan Sucak; Günter Dilsiz; Sahika Zeynep Akı; Zeynep Arzu Yeğin
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

10.  Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications.

Authors:  I I Raad; A M Chaftari; M M Al Shuaibi; Y Jiang; W Shomali; J E Cortes; B Lichtiger; R Y Hachem
Journal:  Ann Oncol       Date:  2013-03-21       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.